Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide

References

• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Attal M, Oliver P, Lauwers-Cances V, et al. Maintenance treatment with lenalidmide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial. Haematologica 2011;96:S23.
   Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366:1759–1769.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012;119:2764–2767.
   PubMed Web of Science ®Google Scholar
• Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med 2011;365:2241–2242.
   PubMed Web of Science ®Google Scholar
• Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012;119:2731–2737.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117: 4701–4705.
   PubMed Web of Science ®Google Scholar
• Dai L, O’Sullivan A, Kennedy R, et al. A randomized clinical trial of lenalidomide and dexamethasone with and without autologous stem cell transplant in patients with newly diagnosed mulitple myeloma: interim study results. Blood 2011;118: Abstract 4142.
   Google Scholar
• Lentzsch S, O’Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608–4613.
   PubMed Web of Science ®Google Scholar
• Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008. pp 87–107.
   Google Scholar
• Bain BJ. The bone marrow aspirate of healthy subjects. Br J Haematol 1996;94:206–209.
   PubMed Web of Science ®Google Scholar
• Matsuda A, Jinnai I, Yagasaki F, et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 1998;12:482–485.
   PubMed Web of Science ®Google Scholar
• Ramos F, Fernandez-Ferrero S, Suarez D, et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res 1999; 23:283–290.
   PubMed Web of Science ®Google Scholar
• Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2006:199–204.
   Google Scholar
• Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification. Leukemia 2007;21:668–677.
   PubMed Web of Science ®Google Scholar
• Romana SP, Radford-Weiss I, Ben Abdelali R, et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia 2006;20: 696–706.
   PubMed Web of Science ®Google Scholar
• Breslow NE, Clayton DG. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993;88:9–25.
   Web of Science ®Google Scholar
• Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 2000;65:123–127.
   Google Scholar
• Cuzick J, Erskine S, Edelman D, et al. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer 1987;55:523–529.
   PubMed Web of Science ®Google Scholar
• Dores GM, Cote TR, Travis LB. New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma and myeloma. In: Curtis RE, Freedman MD, Ron E, et al., editors. New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. NIH Publ. No. 05-5302. Bethesda, MD: National Cancer Institute; 2006. pp 397–434.
   Google Scholar
• Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011;118:4086–4092.
   PubMed Web of Science ®Google Scholar
• Bergsagel DE, Bailey AJ, Langley GR, et al. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743–748.
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996;95:349–353.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Buadi F, McClune B, et al. Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2007; 40:759–764.
   PubMed Web of Science ®Google Scholar
• Landgren O, Ma W, Kyle RA, et al. Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia 2012; 26:844–845.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 2012; 120:1597–1600.
   PubMed Web of Science ®Google Scholar
• Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010;115:605–614.
   Google Scholar
• Liu A, Donnenberg A, Li S, et al. IMiD(R) immunomodulatory drugs lenalidomide and pomalidomide inhibit the maturation of megakaryocytes by suppressing the expression of GATA1. Blood 2011;118: Abstract 1840.
   Google Scholar
• Monaghan SA, Surti U, Doty K, et al. Altered neutrophil maturation patterns that limit identification of myelodysplastic syndromes. Cytometry B Clin Cytom 2012;82:217–228.
   PubMed Web of Science ®Google Scholar
• Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002;34:354–362.
   PubMed Web of Science ®Google Scholar
• De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003;102:2638–2641.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003;102:2568–2573.
   PubMed Web of Science ®Google Scholar
• Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59:2776–2780.
   PubMed Web of Science ®Google Scholar
• Melnick A, Fruchtman S, Zelent A, et al. Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. Leukemia 1999;13:1534–1538.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Dalvi R, Mandava S, et al. Acute myelogeneous leukemia (M0/M1) with novel chromosomal abnormality of t(14;17)(q32;q11.2). Am J Hematol 2007;82:676–678.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Bacher U, Schnittger S, et al. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events. Genes Chromosomes Cancer 2012;51: 328–337.
   PubMed Web of Science ®Google Scholar
• Amiel A, Fridman K, Elis A, et al. Deletion 5q31 in patients with stable, melphalan-treated multiple myeloma. Cancer Genet Cytogenet 1999;113:45–48.
   PubMed Web of Science ®Google Scholar
• Amiel A, Yukla M, Yogev S, et al. Deletion of 5q31 and 7q31 in patients with stable melphalan treated multiple myeloma. Cancer Genet Cytogenet 2004;152:84–87.
   PubMed Web of Science ®Google Scholar
• Nilsson T, Nilsson L, Lenhoff S, et al. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q). Genes Chromosomes Cancer 2004;41:223–231.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008;111:94–100.
   Web of Science ®Google Scholar
• Block AW, Carroll AJ, Hagemeijer A, et al. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:401–412.
   PubMed Web of Science ®Google Scholar
• Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood 2011;118:6247–6257.
   PubMed Web of Science ®Google Scholar
• Kobzev YN, Martinez-Climent J, Lee S, et al. Analysis of translocations that involve the NUP98 gene in patients with 11p15 chromosomal rearrangements. Genes Chromosomes Cancer 2004; 41:339–352.
   PubMed Web of Science ®Google Scholar
• Beyer V, Castagne C, Muhlematter D, et al. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventionalcytogenetics. Cancer Genet Cytogenet 2004;152:29–41.
   Google Scholar
• Cherry AM, Brockman SR, Paternoster SF, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res 2003;27:1085–1090.
   PubMed Web of Science ®Google Scholar
• Costa D, Valera S, Carrio A, et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?Leuk Res 2010;34:1437–1441.
   PubMed Web of Science ®Google Scholar
• Jiang H, Xue Y, Wang Q, et al. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. Leuk Res 2012;36:448–452.
   PubMed Web of Science ®Google Scholar
• Ketterling RP, Wyatt WA, VanWier SA, et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of “FISH panel testing” and M-FISH. Leuk Res 2002;26:235–240.
   PubMed Web of Science ®Google Scholar
• Pitchford CW, Hettinga AC, Reichard KK. Fluorescence in situ hybridization testing for + 5/5q, + 7/7q, + 8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study. Am J Clin Pathol 2010;133:260–264.
   PubMed Web of Science ®Google Scholar
• Bernasconi P, Cavigliano PM, Boni M, et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 2003;17:2107–2112.
   Google Scholar
• Rigolin GM, Bigoni R, Milani R, et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 2001;15:1841–1847.
   PubMed Web of Science ®Google Scholar
• Romeo M, Chauffaille Mde L, Silva MR, et al. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res 2002;26:993–996.
   PubMed Web of Science ®Google Scholar
• Yang W, Stotler B, Sevilla DW, et al. FISH analysis in addition to G-band karyotyping: utility in evaluation of myelodysplastic syndromes?Leuk Res 2010;34:420–425.
   PubMed Web of Science ®Google Scholar
• Makishima H, Rataul M, Gondek LP, et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res 2010;34:447–453.
   PubMed Web of Science ®Google Scholar
• Rossi AC, Mark TM, Jayabalan D, et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). J Clin Oncol 2011;29: Abstract 8008.
   Google Scholar